U.S. drug developer Novavax has started a mid-stage study of its experimental COVID-19 vaccine in South Africa. The company says the study will be conducted on about 2,665 healthy adults and will evaluate safety and immunogenicity in about 240 medically stable HIV-positive adults. South Africa is the world's fifth-worst affected country with 583,653 recorded coronavirus cases and 11,677 deaths. The Bill and Melinda Gates Foundation is giving a grant of 15 million U.S. dollars toward the clinical trial.

Subscribe to us on YouTube: https://goo.gl/lP12gA
Download our APP on Apple Store (iOS): https://itunes.apple.com/us/app/cctvnews-app/id922456579?l=zh&ls=1&mt=8
Download our APP on Google Play (Android): https://play.google.com/store/apps/details?id=com.imib.cctv

Follow us on:
Website: https://www.cgtn.com/
Facebook: https://www.facebook.com/ChinaGlobalTVNetwork/
Twitter: https://twitter.com/CGTNOfficial
Instagram: https://www.instagram.com/cgtn/?hl=zh-cn
Pinterest: https://www.pinterest.com/CGTNOfficial/
Weibo: http://weibo.com/cctvnewsbeijing
Douyin: http://v.douyin.com/aBbmNQ/